Modified Citrus Pectin Alleviates Cerebral Ischemia/Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation via TLR4/NF-ĸB Signaling Pathway in Microglia
DOI: https://doi.org/10.2147/JIR.S366927
IF: 4.5
2022-06-09
Journal of Inflammation Research
Abstract:Yu Cui, 1, 2 Nan-Nan Zhang, 1 Dan Wang, 1 Wei-Hong Meng, 2 Hui-Sheng Chen 1 1 Department of Neurology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China; 2 Department of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, People's Republic of China Correspondence: Hui-Sheng Chen, Department of Neurology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China, Email Wei-Hong Meng, Department of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, People's Republic of China, Email Background: Galectin-3 acts as a mediator of microglial inflammatory response following stroke injury. However, it remains unclear whether inhibiting galectin-3 protects against cerebral ischemia/reperfusion injury. We aimed to investigate the neuroprotective effects of modified citrus pectin (MCP, a galectin-3 blocker) in ischemic stroke and underlying mechanisms. Methods: The middle cerebral artery occlusion/reperfusion (MCAO/R) model in C57BL/6J mice and oxygen-glucose deprivation/reoxygenation (ODG/R) model in neuronal (HT-22) and microglial (BV-2) cells were utilized in the following experiments: 1) the neuroprotective effects of MCP with different concentrations were evaluated in vivo and in vitro through measuring neurological deficit scores, brain water content, infarction volume, cell viability, and cell apoptosis; 2) the mechanisms of its neuroprotection were explored in mice and microglial cells through detecting the expression of NLRP3 (NOD-like receptor 3) inflammasome-related proteins by immunofluorescence staining and Western blotting analyses. Results: Among the tested concentrations, 800 mg/kg/d MCP in mice and 4 g/L MCP in cells, respectively, showed in vivo and in vitro neuroprotective effects on all the tests, compared with vehicle group. First, MCP significantly reduced neurological deficit scores, brain water content and infarction volume, and alleviated cell injury in the cerebral cortex of MCAO/R model. Second, MCP increased cell viability and reduced cell apoptosis in the neuronal OGD/R model. Third, MCP blocked galectin-3 and decreased the expression of TLR4 (Toll-like receptor 4)/NF-κBp65 (nuclear factor kappa-B)/NLRP3/cleaved-caspase-1/IL-1β (interleukin-1β) in microglial cells. Conclusion: This is the first report that MCP exerts neuroprotective effects in ischemic stroke through blocking galectin-3, which may be mediated by inhibiting the activation of NLRP3 inflammasome via TLR4/NF-κB signaling pathway in microglia. Keywords: cerebral ischemia/reperfusion injury, microglia, galectin-3, modified citrus pectin, NLRP3 inflammasome Stroke is the second most common cause of death and major cause of disability worldwide, most of which were ischemic stroke. 1 Although intravenous thrombolysis with recombinant tissue plasminogen activator is the most accessible reperfusion therapy for ischemic stroke, cerebral ischemia/reperfusion injury limits the benefit, which is a severe complication of thrombolytic therapy. 2,3 Accumulating evidences suggest that microglia-mediated neuroinflammatory responses play critical and complex roles in the ischemia/reperfusion injury. 4–7 Galectin-3, as a pleiotropic endogenous protein, is reported to act as a Toll-like Receptor 4 (TLR4) ligand and promote microglial activation and proliferation in stroke. 8–10 In the activated microglia, NOD-like receptor 3 (NLRP3) inflammasome is subsequently activated to increase the release of inflammatory cytokines, 11 which further deteriorate brain injury in the early phase after ischemic stroke. 12 Modified citrus pectin (MCP) is known as a blocker of galectin-3 to inhibit its activity through binding to the carbohydrate recognition domains on galectin-3. 13 Recently, in several diseases, MCP was proven to exert anti-inflammatory effect by blocking galectin-3. 14–17 Furthermore, higher plasma galectin-3 levels were found to be associated with poor functional outcomes after acute ischemic stroke. 18–23 Collectively, cerebral ischemic insult may promote the expression of galectin-3 in microglia, and then trigger the activation of NLRP3 inflammasome in microglia through TLR4/NF-κB signaling pathway, which converts caspase-1 into cleaved-caspase-1. In this context, we argue that blocking galectin-3 by MCP will exert neuroprotective effect in ischemic stroke. However, up to date, no studies have been found to investigate the issue. In the present study, we first used in vivo experiments to evaluate whether MCP prevented cerebral ischemia/reperfusion injury by blocking galect -Abstract Truncated-
immunology